Compare WAFD & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | ZLAB |
|---|---|---|
| Founded | 1917 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 1996 | 2017 |
| Metric | WAFD | ZLAB |
|---|---|---|
| Price | $36.29 | $26.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $35.00 | ★ $49.60 |
| AVG Volume (30 Days) | 406.7K | ★ 1.3M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | 5.20 | ★ 38.46 |
| EPS | ★ 2.45 | N/A |
| Revenue | $29,650,000.00 | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $4.15 | $26.03 |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | 7.79 | ★ 15.33 |
| 52 Week Low | $26.31 | $15.96 |
| 52 Week High | $39.49 | $34.72 |
| Indicator | WAFD | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 67.47 |
| Support Level | $34.18 | $16.84 |
| Resistance Level | $36.12 | $27.08 |
| Average True Range (ATR) | 0.55 | 0.87 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 27.12 | 84.97 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.